Table 1 Demographics and baseline characteristics
Zonisamide | Placebo | |
|---|---|---|
Number (M:F) | 14 (9:5) | 15 (9:6) |
Age, years | 69.9 (5.6) | 67.2 (7.3) |
Weight, kg | 63.9 (10.2) | 61.7 (13.5) |
DaT-SPECT SBR | 6.563 (1.058) | 6.834 (1.873) |
DaT abnormal, n (%) | 2 (14.3) | 4 (26.7) |
MIBG early | 1.88 (0.47) | 1.77 (0.52) |
MIBG delay | 1.55 (0.47) | 1.59 (0.73) |
MIBG washout ratio, % | 57.95 (15.87) | 57.24 (25.44) |
MIBG abnormal, n (%) | 13 (92.9) | 13 (86.7) |
MDS-UPDRS total | 9.4 (6.8) | 11.9 (4.9) |
MDS-UPDRS I | 4.8 (2.5) | 6.5 (2.5) |
MDS-UPDRS II | 1.3 (2.1) | 1.8 (2.1) |
MDS-UPDRS III | 3.4 (3.3) | 3.5 (2.3) |
MoCA-J | 24.6 (3.4) | 25.5 (2.3) |
Stroop test part II – part I, sec | 11.5 (5.0) | 11.1 (8.4) |
Trail making test part B – part A, sec | 65.7 (36.9) | 65.4 (32.6) |
Line orientation test | 17.7 (1.9) | 17.0 (3.6) |
Pareidolia test | 0.3 (0.8) | 0.3 (0.6) |
OSIT-J | 4.2 (3.4) | 5.7 (2.8) |
CVRR rest, % | 2.1 (1.1) | 3.1 (2.8) |
CVRR deep breath, % | 3.1 (1.7) | 4.0 (1.8) |
PASE | 106.1 (50.7) | 73.2 (54.2) |
SCOPA-AUT | 7.6 (4.4) | 8.7 (5.9) |
SAOQ, % | 55.1 (40.5) | 61.8 (29.5) |
RBDSQ | 5.6 (3.7) | 6.7 (2.7) |
ESS | 7.4 (5.4) | 5.3 (3.6) |
BDI-II | 6.4 (7.5) | 5.8 (6.8) |
PDQ-39 summary index | 7.5 (6.5) | 8.0 (7.4) |
QUIP | 0.4 (0.6) | 0.3 (0.6) |
NfL, pg/mL | 14.25 (5.44) | 12.85 (3.31) |
